CAS: 1070790-89-4; (2R,3S)-3-((6-(((4,6-Dimethylpyridin-3-yl)Methyl)Amino)-9-Isopropyl-9H-Purin-2-yl)Amino)Pentan-2-Ol

该化合物是选择性的,强大的,强大的,依赖环球的抑制性动脉(CDK),主要针对CDK2和CDK9. 它的行动机制涉及破坏细胞循环过程和转录调节,使其成为肿瘤研究的有希望的候选体,特别是由CDK受监管的疾病引发的癌症. Fadraciclib表现出高度的特质和有利的药源动力特性,使得肿瘤在临床前的模型中能够有效抑制生长.它的双重目标能力将其与其他CDK抑制性物质区分开来,为克服抗药机制提供了潜在的优势. 该化合物目前正在临床试验中进行各种恶性肿瘤的调查,表明其在推进有针对性的癌症疗法方面的相关性.

结构式图片

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-2023104823-A1
    优先权日:2020-01-22
    标 题:Process for the preparation of purine derivatives exhibiting cdk inhibitory activity
    发明人:SKEAD BENJAMIN; LONDESBROUGH DEREK; GILL CHRIS; HUDSON ALEX
    权利人:CYCLACEL LTD
    摘要:The present invention relates to a process for preparing a compound of formula [I], or a pharmaceutically acceptable salt thereof, said process comprising the steps of: (i) forming a reaction mixture comprising a compound of formula [II] and a compound of formula [III]; (ii) heating said reaction mixture to a temperature of at least about 130° C. to form a compound of formula [I]; (iii) isolating said compound of formula [I] from the mixture and optionally recovering unreacted compound of formula [III]; and (iv) optionally converting said compound of formula [I] into salt form; wherein: R1 and R2 are each independently H, alkyl or haloalkyl; R3 and R4 are each independently H, alkyl, haloalkyl or aryl; R5 is alkyl, alkenyl, cycloalkyl or cycloalkyl-alkyl, each of which may be optionally substituted with one or more OH groups; R6 is selected from cyclopropylamino, cyclopropylmethylamino, cyclobutylamino, cyclobutylmethylamino and where one of X, Y and Z is N and the remainder are CR9; R7, R8 and each R9 are independently H, alkyl or haloalkyl, wherein at least one of R7, R8 and R9 is other than H. Further aspects of the invention relate to a process for preparing intermediates of formula [II], and other intermediates useful in the synthesis of compounds of formula [I].

    专利号:US-10927113-B2
    优先权日:2017-01-26
    标 题 :Process for preparing purine derivatives
    发明人:SKEAD BENJAMIN MARK; WESTWOOD ROBERT; LONDESBROUGH DEREK; NORTHEN JULIAN SCOTT; ATHERTON JONATHAN CHARLES CHRISTIAN
    权利人:CYCLACEL LTD
    摘要:The present invention relates to a process for preparing a compound of formula [I], said process comprising the steps of: formula [II]+formula [III]→formula [I] (i) forming a reaction mixture comprising (a) a compound of formula [II], (b) a compound of formula [III] and (c) 1,2-propanediol or polyethylene glycol, or a mixture thereof, and optionally (d) a base; (ii) heating said reaction mixture to a temperature of at least about 150° C. to form a compound of formula [I]; (iii) isolating said compound of formula [I]; and (iv) optionally converting said compound of formula [I] into salt form; wherein: R 1 and R 2 are each independently H, alkyl or haloalkyl; R 3 and R 4 are each independently H, alkyl, haloalkyl or aryl; R 5 is alkyl, alkenyl, cycloalkyl or cycloalkyl-alkyl, each of which may be optionally substituted with one or more OH groups; R 6 is selected from cyclopropylamino, cyclopropylmethylamino, cyclobutylamino, cyclobutylmethylamino and formula (A) where one of X, Y and Z is N and the remainder are CR 9 ; R 7 , R 8 and each R 9 are independently H, alkyl or haloalkyl, wherein at least one of R 7 , R 8 and R 9 is other than H. Further aspects of the invention relate to a highly diastereoselective process for the preparation of compounds of formula [III], a process for preparing intermediates of formula [II], and other intermediates useful in the synthesis of compounds of formula [I], and to a process for preparing the crystalline tartrate salt and free base of compounds of formula [I].

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Frame S, Saladino C, MacKay C, Atrash B, Sheldrake P, McDonald E, Clarke PA, Workman P, Blake D, Zheleva D. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLoS One. 2020 Jul 9;15(7):e0234103. doi: 10.1371/journal.pone.0234103. Erratum in: PLoS One. 2021 May 6;16(5):e0251671.
    2: Chen R, Chen Y, Xiong P, Zheleva D, Blake D, Keating MJ, Wierda WG, Plunkett W. Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti- apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells. Leukemia. 2022 Jun;36(6):1596-1608. doi: 10.1038/s41375-022-01553-w. Epub 2022 Apr 5.
    3: PLOS ONE Staff. Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLoS One. 2021 May 6;16(5):e0251671. doi: 10.1371/journal.pone.0251671. Erratum for: PLoS One. 2020 Jul 9;15(7):e0234103.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知